Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire

Saved in:
Bibliographic Details
Published inDiabetologia Vol. 53; no. 1; pp. 1 - 6
Main Authors Butler, P. C, Matveyenko, A. V, Dry, S, Bhushan, A, Elashoff, R
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Berlin/Heidelberg : Springer-Verlag 01.01.2010
Springer-Verlag
Springer Nature B.V
Subjects
Animals
Commentary
Disease Models, Animal
Glucagon-Like Peptide 1 - therapeutic use
Human Physiology
Humans
Hyperplasia - drug therapy
Internal Medicine
Medicine
Medicine & Public Health
Metabolic Diseases
Pancreas, Exocrine - drug effects
Pancreatic Ducts - drug effects
Pancreatic Ducts - pathology
Pancreatitis - drug therapy
Pancreatitis, Chronic - drug therapy
Pancreatitis, Chronic - physiopathology
Rats
United States
United States Food and Drug Administration
United States
Type 2 diabetes
Glucagon-like peptide-1
GLP-1
Pancreatic cancer
Pancreatitis
Online AccessGet full text

Cover

More Information
Bibliography:http://dx.doi.org/10.1007/s00125-009-1591-5
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:0012-186X
1432-0428
DOI:10.1007/s00125-009-1591-5